Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to investigate whether Müllerian inhibiting substance (MIS) in combination with calcitriol modulates proliferation and apoptosis of human ovarian cancer (OCa) cell lines (SKOV3, OVCAR3, and OVCA433) and identify the signaling pathway by which MIS mediates apoptosis. Materials and Methods: OCa cell lines were treated with MIS in the absence or presence of calcitriol. Cell viability and proliferationwere evaluated using the Cell Counting Kit-8 assay and apoptosis was evaluated by DNA fragmentation assay. Western blot and enzyme-linked immunosorbent assay were used to determine the signaling pathway. Results: The cells showed specific staining for the MIS type II receptor. Treatment of OCa cells with MIS and calcitriol led to dose- and time-dependent inhibition of cell growth and survival. The combination treatment significantly suppressed cell growth, down-regulated the expression of B-cell lymphoma 2 (Bcl-2), and up-regulated the expressions of Bcl-2 associated X protein, caspase-3, and caspase-9 through the extracellular signal-regulated kinase signaling pathway. Conclusion: These results, coupled with a much-needed decrease in the toxic side effects of currently employed therapeutic agents, provide a strong rationale for testing the therapeutic potential of MIS, alone or in combination with calcitriol, in the treatmentof OCa.
Abstract
Purpose: This study aimed to investigate whether Müllerian inhibiting substance (MIS) in combination with calcitriol modulates proliferation and apoptosis of human ovarian cancer (OCa) cell lines (SKOV3, OVCAR3, and OVCA433) and identify the signaling pathway by which MIS mediates apoptosis. Materials and Methods: OCa cell lines were treated with MIS in the absence or presence of calcitriol. Cell viability and proliferationwere evaluated using the Cell Counting Kit-8 assay and apoptosis was evaluated by DNA fragmentation assay. Western blot and enzyme-linked immunosorbent assay were used to determine the signaling pathway. Results: The cells showed specific staining for the MIS type II receptor. Treatment of OCa cells with MIS and calcitriol led to dose- and time-dependent inhibition of cell growth and survival. The combination treatment significantly suppressed cell growth, down-regulated the expression of B-cell lymphoma 2 (Bcl-2), and up-regulated the expressions of Bcl-2 associated X protein, caspase-3, and caspase-9 through the extracellular signal-regulated kinase signaling pathway. Conclusion: These results, coupled with a much-needed decrease in the toxic side effects of currently employed therapeutic agents, provide a strong rationale for testing the therapeutic potential of MIS, alone or in combination with calcitriol, in the treatmentof OCa.
참고문헌 (29)
- Jemal A, "Cancer statistics, 2003", CA Cancer J Clin, 53, pp.5~26 (2003)
- Berkenblit A, "Advances in the management of epithelial ovarian cancer", J Reprod Med, 50, pp.426~438 (2005)
- Salom E, "Management of recurrent ovarian cancer: evidence-based decisions", Curr Opin Oncol, 14, pp.519~527 (2002)
- MacLaughlin DT, "Perspective: reproductive tract development--new discoveries and future directions", Endocrinology, 142, pp.2167~2172 (2001)
- Coughlin JP, "Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase", Mol Cell Endocrinol, 49, pp.75~86 (1987)
- Gupta V, "Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model", Proc Natl Acad Sci U S A, 102, pp.3219~3224 (2005)
- Segev DL, "Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway", J Biol Chem, 275, pp.28371~28379 (2000)
- Renaud EJ, "Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance", Proc Natl Acad Sci U S A, 102, pp.111~116 (2005)
- Barbie TU, "Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107", Proc Natl Acad Sci U S A, 100, pp.15601~15606 (2003)
- MacLaughlin DT, "Müllerian inhibiting substance", anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers, 2010, pp.6, 391~405
- Ponsonby AL, "Vitamin D status during pregnancy and aspects of offspring health", Nutrients, 2, pp.389~407 (2010)
- Giammanco M, "Vitamin D in cancer chemoprevention", Pharm Biol, 53, pp.1399~1434 (2015)
- Malloy PJ, "Interaction of the vitamin D receptor with a vitamin D response element in the Mullerianinhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells", Endocrinology, 150, pp.1580~1587 (2009)
- Krishnan AV, "Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer", J Steroid Biochem Mol Biol, 103, pp.694~702 (2007)
- Hoshiya Y, "Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells", Mol Cell Endocrinol, 211, pp.43~49 (2003)
- Parry RL, "Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo", Cancer Res, 52, pp.1182~1186 (1992)
- 김현석, "Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine", Yonsei Medical Journal, 56(5), pp.1186~1198 (2015), 연세대학교의과대학[DOI]
- Namkung J, "Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis", J Clin Endocrinol Metab, 97, pp.3224~3230 (2012)
- Leyssens C, "Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer", Endocr Relat Cancer, 20, pp.R31~R47 (2013)
- Pereira F, "Vitamin D and colon cancer", Endocr Relat Cancer, 19, pp.R51~R71 (2012)
- Swami S, "Vitamin D metabolism and action in the prostate: implications for health and disease", Mol Cell Endocrinol, 347, pp.61~69 (2011)
- Krishnan AV, "Molecular pathways mediating the antiinflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment", Endocr Relat Cancer, 17, pp.R19~R38 (2010)
- Gocek E, "Vitamin D and differentiation in cancer", Crit Rev Clin Lab Sci, 46, pp.190~209 (2009)
- Haussler MR, "Molecular mechanisms of vitamin D action", Calcif Tissue Int, 92, pp.77~98 (2013)
- Kasiappan R, "1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498", J Biol Chem, 287, pp.41297~41309 (2012)
- Daniel C, "The TGFbeta", Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression, 2007, pp.102, 1420~1431
- Tu H, "Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial", Mol Carcinog, 54, pp.270~280 (2015)
- Bizzarri M, "Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures", J Surg Res, 110, pp.332~337 (2003)
- Renlund N, "c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction", Endocrinology, 149, pp.108~115 (2008)